Dealing with Primary Membranous Nephropathy?
Discover Hope Through Clinical Trials
Primary Membranous Nephropathy (PMN) is a rare, immune-mediated kidney condition that causes the kidneys to leak large amounts of protein into the urine; a condition known as proteinuria. Over time, this can lead to nephrotic syndrome, chronic kidney damage, and even kidney failure if left untreated.
PMN is most often associated with antibodies against the phospholipase A2 receptor (PLA2R) found on podocytes, the kidney’s filtration cells. These antibodies trigger an autoimmune response, damaging the filtering units of the kidneys and causing inflammation.
Revival Research Institute is conducting Primary Membranous Nephropathy Clinical Trials to explore innovative treatment options. These studies aim to assess the safety and efficacy of investigational therapy designed to target B cells involved in disease progression. The trial aims to assess the safety and effectiveness of this treatment in slowing or potentially reversing kidney damage caused by PMN.
Are You Eligible to Participate?
To participate in our clinical trial for Primary Membranous Nephropathy, individuals must meet the following criteria:
- Age between 18 to 70 years
- Diagnosed with Primary Membranous Nephropathy (PLA2R-positive)
- Urine protein-creatinine ratio (UPCR) of ≥ 2.0 g/g
*Additional criteria may apply.
Participation in Primary Membranous Nephropathy clinical trials in Texas or other locations provides a chance to receive expert care, free study-related medication, and regular health monitoring by experienced medical professionals.
